Abstract
Background: In 2001, Cuba launched a national ARV access program to provide ARV therapy free of cost. The first-line therapy combinations are composed of two nucleoside reverse transcriptase (RT) inhibitors (NRTIs) (AZT+3TC or d4T+3TC) associated with a non-nucleoside RT inhibitor (NNRTI) (NVP or EFV) or a protease inhibitor (PI) (IDV). Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112918/
Highlights
In 2001, Cuba launched a national ARV access program to provide ARV therapy free of cost
The first-line therapy combinations are composed of two nucleoside reverse transcriptase (RT) inhibitors (NRTIs) (AZT +3TC or d4T+3TC) associated with a non-nucleoside RT inhibitor (NNRTI) (NVP or EFV) or a protease inhibitor (PI) (IDV)
Plasma samples from 84 HIV-1 infected patients were collected from June to November 2009 at the Tropical Medicine Institute from Havana City
Summary
Molecular epidemiology of antiretroviral resistance in therapy-experienced HIV-1 patients in Cuba (2009). L Pérez1*, J Aleman, C Correa, J Pérez, C Fonseca, C Aragones, D Pérez, A Alvarez, AM Vandamme, V Kourí, K Van Laethem. From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK. From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 7-11 November 2010
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
